Evolent Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on June 3, 2025. The filing serves as a Regulation FD disclosure regarding an upcoming presentation by the management team at the William Blair 45th Annual Growth Stock Conference in Chicago, Illinois.
Key Financial Metrics and Guidance
The filing does not report historical financial results for a specific period but focuses on reaffirming forward-looking guidance for 2025 and the second quarter of 2025. The key metrics provided are:
- 2025 Full Year Revenue Guidance: Approximately $2.06 billion to $2.11 billion.
- 2025 Full Year Adjusted EBITDA Guidance: Approximately $135.0 million to $165.0 million.
- Q2 2025 Revenue Guidance: Approximately $440.0 million to $470.0 million.
- Q2 2025 Adjusted EBITDA Guidance: $33.0 million to $40.0 million.
The filing states that the Company cannot meaningfully reconcile non-GAAP Adjusted EBITDA guidance to net income due to the inability to forecast significant reconciling items without unreasonable effort.
Material Changes and Outlook
There are no material changes to financial performance reported in this filing. The guidance reaffirmed is consistent with the press release issued on May 8, 2025. Management expects to present this information during the conference on June 3, 2025, with a live audio webcast available on the investor relations website.
Risks, Contingencies, and Unusual Items
The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to various risks and uncertainties detailed in the Company's 2024 Form 10-K and Q1 2025 Form 10-Q. Specific items that prevent the reconciliation of Adjusted EBITDA to net income include:
- Loss on repayment or extinguishment of debt.
- Gain or loss from equity method investees.
- Changes in fair value of contingent consideration and tax receivable agreement liability.
- Stock-based compensation, severance costs, and transaction-related costs.
- Impairments of right-of-use assets and losses on lease terminations.
The exact amounts of these adjustments are not currently determinable but may be significant.
Investor Verification Checklist
- Verify the consistency of the reaffirmed guidance with the May 8, 2025 press release.
- Review the Company's 2024 Form 10-K and Q1 2025 Form 10-Q for detailed risk factors and historical financial performance.
- Monitor the live webcast or replay on the investor relations website for any additional commentary not captured in this filing.
- Note that the filing explicitly states it does not provide a reconciliation of Adjusted EBITDA to net income for future periods.